newsfilter
← Latest News
Business Wire·

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel